Biopharmaceutical outperformers tend to double down on early innovation. According to our analysis, between 2003 and 2007, outperformers sourced 61 percent of their assets at the preclinical stage—compared with 49 percent for others in the group. That number grew to 74 percent between 2018 and the beginning of December 2021.
To read the article, see “Innovation sourcing in biopharma: Four practices to maximize success,” May 31, 2022.